Asafoetida and PCOS
What 2 graded rows on asafoetida agree on for PCOS, and where they differ. Counted side by side, never averaged.
Consensus finder Rows from the Asafoetida page, reviewed Oct 21, 2026 How it decides
What the rows agree on
Each block and row is one graded row from the Asafoetida page, with its PubMed record.
Your question
Asafoetida and PCOS
2 rows · 73 peopleInconsistent: both rows reported mixed results.
- DGrade D× 2
- Rows
- 2
- Trials
- 2
- People
- 73
What the rows share
From the rowsThe best-graded row, grade D, is a randomized trial of 43 people (2023) and reported mixed results.
Each row reported mixed results on its own, so there is no side to compare. The rows enrolled 30 to 43 people and were published from 2023 to 2024.
The rows
2 mixed- DGrade DOvarian follicles and hormones in polycystic ovary syndrome (placebo-controlled) · Mixed
RCT · n 43 · 2023 · Young women with polycystic ovary syndrome in Iran (47 enrolled, 43 analysed)
100 mg twice daily (200 mg/day; from the full text) · 3 months
Ovarian follicle counts fell versus placebo, and DHEAS and TSH levels changed significantly versus placebo (p < 0.03). The full text reports no significant between-group change in clinical measures (BMI, hair growth score, menstruation duration).
- DGrade DMenstrual regularity and pregnancy in polycystic ovary syndrome · Mixed
RCT · n 30 · 2024 · Women with polycystic ovary syndrome (15 per group)
1 g/day · Two 21-day courses with a 7-day break; follow-up 8 months
More pregnancies occurred after asafoetida than after the contraceptive (p = 0.019), and regular cycles lasted longer (p = 0.001). Cycle intervals shortened in both groups; lipids rose only with the contraceptive.